Trial Profile

A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of GEC255 Oral Tablets in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GEC-255 (Primary)
Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors GenEros BioPharma

Most Recent Events

01 Jun 2023 According to a GenEros Biopharma Media Release, preliminary data (As of the data cutoff date: 3 February 2023; n=16) from this study will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting June 4, 2023, at 8:00-GMT-5 11:00.
01 Jun 2023 Results presented in a GenEros Biopharma Media Release.
17 Mar 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com